Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), Dengue, Cytomegalovirus (CMV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients) and Geography
The vaccines market was valued at US$ 39,128.3 million in 2019 and is projected to reach US$ 64,538.4 million by 2027; it is expected to grow at a CAGR of 6.5% from 2020 to 2027.
A vaccine is a biological preparation that provides active acquired immunity against a particular disease. A vaccine consists of an agent that resembles or is a part of the disease-causing microorganism and is often made from weakened or killed forms of the microorganism, its toxins, or one of its surface proteins. The agent triggers the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
The scope of the vaccines market includes technology, disease indication, route of administration, patient type, and region. The market for vaccinesis analyzed based on regions such as North America, Europe, Asia Pacific, Middle East & Africa, and South and Central America. The report offers insights and in-depth analysis of the vaccines market emphasizing on various parameters such as market trends, technological advancements, market dynamics, and competitive landscape analysis of leading market players across the world
Lucrative Regions for Vaccines Market
Get more information on this report :
Market Insights
Rising prevalence of infectious diseasesis expected to boost the market growth over the years
In the current era, there are increasing concerns of spread of infectious diseases with the changing environment. These emerging infectious diseases are a burden on public health but have also an impact on global economies. The new diseases such as HIV, hepatitis, dengue have attracted a huge concern for the government of the respective countries. There is also resurgence of diseases which seemed to be under control such as malaria, cholera and many more. According to the Centers for Disease control and Prevention in 2015, 16.8 million people in the US visited hospitals due to infectious and parasitic diseases. In Africa, chronic viral hepatitis affects around 70 million Africans (60 million with Hepatitis B and 10 million with Hepatitis C). The disease impacts the most important part of the African population i.e. youths and earning African population which are causing tremendous rise in financial debts incurred for the treatment of advanced liver diseases and emotional distress.In developed countries, the cases of infectious diseases has decreased in the past decade, but there has been a rise of re-emerging diseases worldwide, such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), measles, avian and pandemic influenza, chikungunya virus, Ebola virus disease (EVD) and Zika virus disease, which has attracted a renewed focus on infectious diseases around the developed countries.Thus the growing global prevalence of infectious diseases are expected to encourage the leading market players for the development of new and effective drugs and vaccines.
Increasing Support for Vaccine Development
In addition to the funds from traditional research-funding institutions, the Gates Foundation has invested hundreds of millions of dollars in R&D of new vaccines against the leading killers of children and adults everywhere. GAVI has established public-private partnerships to accelerate late-stage development and introduction of priority vaccines against diseases such as rotavirus and pneumococcus. These partnerships are designed to work with governments, donors, and industry to streamline demand, supply, and financing decisions. They coordinate and fund the efforts of partners supporting national decision makers whether to introduce these new products, ensuring a reliable and sustainable supply of affordable vaccine to developing countries, and reducing risks and creating incentives for private investment to ensure access to the product. Global Vaccine Fund commits $150 Million in vaccines and funding over five years to 13 developing countries. Countries will receive financial and technical assistance in order to strengthen basic immunization systems and to introduce newer, under-used vaccines such as hepatitis B and Haemophilusinfluenzae type b (Hib). Some countries will receive support in both areas. Thus the growing support for vaccine development is likely to favor market growth.
TechnologyInsights
The vaccines market by technology is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines, inactivated vaccines, and toxoid vaccines. In 2019, the conjugate vaccines segment held a largest market share in the vaccines market, By Technology. This segment is also expected to dominate the market in 2027 as they are the most effective forms of immunization, used to prevent diseases in both infants and adults. Moreover, the similar segment is anticipated to also witness the fastest growth rate during the forecast period.
Patient Type Insights
The global vaccines market on the patient type is segmented into pediatric patients and adult patients. In 2019, the pediatric segment held a largest market share in the vaccines market, by patient type. This segment is also expected to dominate the market in 2027 as external immunization is necessary for the new borns. Moreover, vaccines have helped the children in staying healthy and been successful to save millions of lives for more than 50 years.
Global Vaccines Market, by Patient Type – 2019 & 2027
Get more information on this report :
Disease Indication Insights
Based on disease indication, the vaccine market is segmented into DTP (diphtheria tetanus toxoids and pertussis), influenza, hepatitis, respiratory syncytial virus (RSV), dengue, cytomegalovirus (CMV), and other diseases. The DTP segment held the largest share of the market in 2019 and is estimated to register the highest CAGR of in the market during the forecast period.
Route of Administration Insights
Based on route of administration, the vaccine market is segmented into oral, injectable, and other routes of administration. In 2019, the injectable segment held the largest share in the market. However, oral route of administration segment is estimated to register the highest CAGR of in the market during the forecast period.
Strategic Insights
Product approvals and collaborationswere observed as the most adopted strategy in global vaccines industry. Few of the recent product key developments are listed below;
2019: Merck, known as MSD outside of the United States and Canada, announced that V114, the company’s investigational 15-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of invasive pneumococcal disease (IPD). The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of drugs intended for serious or life-threatening conditions.
2018: The European Commission has granted marketing authorization for Dengvaxia, Sanofi’s dengue vaccine. The marketing authorization follows the October 18, 2018, recommendation by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas.
2018: Pfizer entered into a multi-year research and development (R&D) collaboration with BioNTech AG to develop mRNA-based vaccines
The emergence of coronavirus pandemic is estimated to have significant impact on the vaccines market. Majority of the pharmaceutical companies around the globe are engaged in the development of vaccine for coronavirus. However, this shift of focus for research and development is anticipated to have negative impact on the other segments of the market. Also, the disruptions in supply chain caused due to shut down of global operations are also projected to have adverse impact on the market by certain extent.
VACCINES– MARKET SEGMENTATION
By Technology
- Recombinant vaccines
- Conjugate Vaccines
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
By Disease Indication
- DTP (diphtheria, tetanus, and pertussis)
- Influenza
- Hepatitis
- Dengue
- Cytomegalovirus (CMV)
- Respiratory Syncytial Virus (RSV)
- Other Diseases
By Route of Administration
- Oral
- Injectable
- Other
By Patient Type
- Adult Patients
- Pediatric Patients
By Geography
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- UK
- Italy
- Spain
- Asia Pacific (APAC)
- China
- Japan
- India
- Australia
- South Korea
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
- South America (SAM)
- Brazil
- Argentina
Company Profiles
- PFIZER INC
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Services, Inc
- Panacea Biotec Limited
- Astellas Pharma Inc.
- NOVAVAX, INC.
- VBI Vaccines Inc.
- Bavarian Nordic
1. Introduction
1.1 Scope Of The Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Vaccines Market – By Technology
1.3.2 Global Vaccines Market – By Disease Indication
1.3.3 Global Vaccines Market – By Route of Administration
1.3.4 Global Vaccines Market – By Patient Type
1.3.5 Global Vaccines Market – By Geography
2. Vaccines Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Vaccines Market – Market Landscape
4.1 Overview
4.2 Pest Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe– PEST Analysis
4.2.3 Asia Pacific– PEST Analysis
4.2.4 Middle East & Africa– PEST Analysis
4.2.5 South and Central America – PEST Analysis
4.3 Expert Opinions
5. Global Vaccines Market – Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Infectious Diseases
5.1.2 Growing Focus on Immunization Programs
5.1.3 Increasing Support for Vaccine Development
5.2 Key Market Restraints
5.2.1 The Complexity And Cost of Vaccine Manufacturing
5.2.2 Soaring Costs of Vaccines
5.3 Key Market Opportunities
5.3.1 Robust Pipeline of Vaccines
5.4 Future Trends
5.4.1 New Vaccine Delivery Systems
5.5 Impact Analysis
6. Vaccines Market – Global Analysis
6.1 Global Vaccines Market Revenue Forecasts And Analysis
6.2 Global Vaccines Market, By Geography - Forecasts And Analysis
6.3 Performance Of Key Players
6.3.1 GlaxoSmithKline plc
6.3.2 Sanofi
7. Vaccines Market - Technology
7.1 Overview
7.2 Vaccines Market Share, Technology, 2019 And 2027 (%)
7.3 Recombinant Vaccinesinant Vaccines
7.3.1 Overview
7.3.2 Recombinant Vaccinesinant Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
7.4 Conjugate Vaccines
7.4.1 Overview
7.4.2 Conjugate Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
7.5 Live Attenuated Vaccines Attenuated Vaccines
7.5.1 Overview
7.5.2 Live Attenuated Vaccines Attenuated Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
7.6 Inactivated and Subunit Vaccines Vaccines
7.6.1 Overview
7.6.2 Inactivated and Subunit Vaccines Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
7.7 Toxoid Vaccines Vaccines
7.7.1 Overview
7.7.2 Toxoid Vaccines Vaccines: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
8. Vaccines Market– Disease Indication
8.1 Overview
8.2 Disease Indication Market Revenue And Forecasts Analysis (Us$ Mn)
8.3 Dtp (Diphtheria, Tetanus, And Pertussis)
8.3.1 Overview
8.3.2 DTP (Diphtheria, Tetanus, And Pertussis): Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
8.4 Influenza
8.4.1 Overview
8.4.2 Influenza: Vaccines Market -Revenue and Forecast to 2027 (US$ Million)
8.5 Dengue
8.5.1 Overview
8.5.2 Dengue: Vaccines Market- Revenue and Forecast to 2027 (US$ Million)
8.6 Cytomegalovirus (CMV)
8.6.1 Overview
8.6.2 Cytomegalovirus (CMV): Vaccines Market -Revenue and Forecast to 2027 (US$ Million)
8.7 Hepatitis
8.7.1 Overview
8.7.2 Hepatitis: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
8.7.3 Hepatitis A
8.7.3.1 Overview
8.7.3.2 Hepatitis A: Hepatitis Market - Revenue and Forecast to 2027 (US$ Million)
8.7.4 Hepatitis B
8.7.4.1 Overview
8.7.4.2 Hepatitis B: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
8.8 Respiratory Syncytial Virus (Rsv)
8.8.1 Overview
8.8.2 Respiratory Syncytial Virus (RSV): Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
8.9 Other Diseases
8.9.1 Overview
8.9.2 Other Diseases: Vaccines Market -Revenue and Forecast to 2027 (US$ Million)
9. Vaccines Market– Route Of Administration
9.1 Overview
9.2 Route Of Administration Market Revenue And Forecasts Analysis (Us$ Mn)
9.3 Oral
9.3.1 Overview
9.3.2 Oral: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Injectable
9.4.1 Overview
9.4.2 Injectable: Vaccines Market -Revenue and Forecast to 2027 (US$ Million)
9.5 Other Routes Of Administrations
9.5.1 Overview
9.5.2 Other Routes of Administration; Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
10. Vaccines Market– Patient Type
10.1 Overview
10.2 Patient Type Market Revenue And Forecasts Analysis (Us$ Mn)
10.3 Paediatric
10.3.1 Overview
10.3.2 Pediatric: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
10.4 Adults Market
10.4.1 Overview
10.4.2 Adults: Vaccines Market - Revenue and Forecast to 2027 (US$ Million)
11. Vaccines Market– Geographical Analysis
11.1 North America: Vaccines Market
11.1.1 Overview
11.1.2 North America: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.1.3 North America: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.1.4 North America: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.1.4.1 North America: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.1.5 North America: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.1.6 North America: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.1.7 North America: Vaccines Market, By Country, 2019 & 2027 (%)
11.1.8 US Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.8.1 US: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.1.8.2 US: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.1.8.2.1 US: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.1.8.3 US: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.1.8.4 US: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.1.9 Canada Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.9.1 Canada: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.1.9.2 Canada: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.1.9.3 Canada: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.1.9.3.1 Canada: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.1.9.4 Canada: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.1.9.5 Canada: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.1.10 Mexico Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.1.10.1 Mexico: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.1.10.2 Mexico: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.1.10.3 Mexico: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.1.10.3.1 Mexico: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.1.10.4 Mexico: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.1.10.5 Mexico: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.2 Europe: Vaccines Market
11.2.1 Overview
11.2.2 Europe: Vaccines Market Revenue, by Country (2019) (US$ Mn)
11.2.3 Europe: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.2.4 Europe: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.2.5 Europe: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.2.5.1 Europe: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.2.6 Europe: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.2.7 Europe: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.2.8 Europe: Vaccines Market, By Country, 2019 & 2027 (%)
11.2.9 Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.9.1 Germany: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.2.9.2 Germany: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.2.9.3 Germany: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.2.9.3.1 Germany: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.2.9.4 Germany: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.2.9.5 Germany: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.2.10 UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.10.1 UK: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.2.10.2 UK: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.2.10.3 UK: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.2.10.3.1 UK: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.2.10.4 UK: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.2.10.5 UK: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.2.11 France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.11.1 France: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.2.11.2 France: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.2.11.3 France: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.2.11.3.1 France: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.2.11.4 France: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.2.11.5 France: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.2.12 Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.12.1 Italy: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.2.12.2 Italy: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.2.12.3 Italy: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.2.12.3.1 Italy: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.2.12.4 Italy: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.2.12.5 Italy: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.2.13 Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.2.13.1 Spain: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.2.13.2 Spain: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.2.13.3 Spain: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.2.13.3.1 Spain: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.2.13.4 Spain: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.2.13.5 Spain: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.3 Asia Pacific Vaccines Market
11.3.1 Overview
11.3.2 Asia Pacific: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.3.3 Asia Pacific: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.3.4 Asia Pacific: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.3.4.1 Asia Pacific: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.3.5 Asia Pacific: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.3.6 Asia Pacific: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.3.7 Asia Pacific: Vaccines Market, By Country, 2018 & 2027 (%)
11.3.8 China Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.8.1 China: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.3.8.2 China: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.3.8.3 China: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.3.8.3.1 China: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.3.8.4 China: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.3.8.5 China: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.3.9 Japan Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.9.1 Japan: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.3.9.2 Japan: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.3.9.3 Japan: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.3.9.3.1 Japan: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.3.9.4 Japan: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.3.9.5 Japan: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.3.10 India Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.10.1 India: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.3.10.2 India: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.3.10.3 India: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.3.10.3.1 India: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.3.10.4 India: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.3.10.5 India: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.3.11 Australia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.11.1 Australia: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.3.11.2 Australia: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.3.11.3 Australia: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.3.11.3.1 Australia: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.3.11.4 Australia: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.3.11.5 Australia: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.3.12 South Korea Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.3.12.1 South Korea: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.3.12.2 South Korea: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.3.12.3 South Korea: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.3.12.3.1 South Korea: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.3.12.4 South Korea: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.3.12.5 South Korea: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.4 Middle East & Africa Vaccines Market
11.4.1 Middle East And Africa: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.4.2 Middle East and Africa: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.4.3 Middle East and Africa: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.4.3.1 Middle East and Africa: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.4.4 Middle East and Africa: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.4.5 Middle East and Africa: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.4.6 Middle East & Africa: Vaccines Market, By Country, 2019 & 2027 (%)
11.4.7 UAE Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.7.1 UAE: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.4.7.2 UAE: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.4.7.3 UAE: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.4.7.3.1 UAE: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.4.7.4 UAE: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.4.7.5 UAE: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.4.8 Saudi Arabia Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.8.1 Saudi Arabia: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.4.8.2 Saudi Arabia: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.4.8.3 Saudi Arabia: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.4.8.3.1 Saudi Arabia: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.4.8.4 Saudi Arabia: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.4.8.5 Saudi Arabia: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.4.9 South Africa Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.4.9.1 South Africa: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.4.9.2 South Africa: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.4.9.3 South Africa: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.4.9.3.1 South Africa: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.4.9.4 South Africa: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.4.9.5 South Africa: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.5 South And Central America Vaccines Market
11.5.1 Overview
11.5.2 South and Central America: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.5.3 South and Central America: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.5.4 South and Central America: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.5.4.1 South and Central America: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.5.5 South and Central America: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.5.6 South and Central America: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.5.7 South and Central America: Vaccines Market, by Country, 2019 and 2027 (%)
11.5.8 Brazil Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.8.1 Brazil: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.5.8.2 Brazil: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.5.8.3 Brazil: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.5.8.3.1 Brazil: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.5.8.4 Brazil: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.5.8.5 Brazil: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
11.5.9 Argentina Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)
11.5.9.1 Argentina: Vaccines Market- Revenue And Forecasts to 2027 (USD Million)
11.5.9.2 Argentina: Vaccines Market, By Technology, 2018-2027 (USD Million)
11.5.9.3 Argentina: Vaccines Market, By Disease Indication, 2018-2027 (USD Million)
11.5.9.3.1 Argentina: Vaccines Market, By Hepatitis, 2018-2027 (USD Million)
11.5.9.4 Argentina: Vaccines Market, By Route of Administration, 2018-2027 (USD Million)
11.5.9.5 Argentina: Vaccines Market, By Patient Type, 2018-2027 (USD Million)
12. Impact Of Covid-19 Pandemic On Global Vaccines Market
12.1 North America: Impact assessment of COVID-19 Pandemic
12.2 Europe: Impact assessment of COVID-19 Pandemic
12.3 Asia-Pacific: Impact assessment of COVID-19 Pandemic
12.4 Rest of World: Impact assessment of COVID-19 Pandemic
13. Vaccines Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies Done By The Companies In The Market, (%)
13.3 Organic Developments
13.3.1 Overview
13.4 Inorganic Developments
13.4.1 Overview
14. Vaccines Market –Key Company Profiles
14.1 Pfizer Inc.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Financial Overview
14.1.4 Product Portfolio
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Glaxosmithkline Plc.
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Financial Overview
14.2.4 Product Portfolio
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Merck & Co., Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Financial Overview
14.3.4 Product Portfolio
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Sanofi
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Financial Information
14.4.4 Product Portfolio
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Johnson & Johnson Services, Inc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Financial Overview
14.5.4 Product Portfolio
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Panacea Biotec Limited
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Financial Information
14.6.4 Product Portfolio
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Astellas Pharma Inc.
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Financial Overview
14.7.4 Product Portfolio
14.7.5 Swot Analysis
14.7.6 Key Developments
14.8 Novavax, Inc.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Financial Information
14.8.4 Product Pipeline
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Vbi Vaccines Inc.
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Financial Information
14.9.4 Product Portfolio
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Bavarian Nordic
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Financial Information
14.10.4 Product Pipeline
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary Of Terms
LIST OF TABLES
Table 1. North America Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 2. North America: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 3. North America: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 4. North America: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 5. North America: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 6. US Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 7. US: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 8. US: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 9. US: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 10. US: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 11. Canada Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 12. Canada: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 13. Canada: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 14. Canada: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 15. Canada: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 16. Mexico Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 17. Mexico: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 18. Mexico: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 19. Mexico: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 20. Mexico: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 21. Europe Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 22. Europe: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 23. Europe: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 24. Europe: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 25. Europe: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 26. Germany Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 27. Germany: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 28. Germany: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 29. Germany: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 30. Germany: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 31. UK Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 32. UK: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 33. UK: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 34. UK: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 35. UK: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 36. France Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 37. France: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 38. France: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 39. France: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 40. France: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 41. Italy Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 42. Italy: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 43. Italy: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 44. Italy: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 45. Italy: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 46. Spain Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 47. Spain: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 48. Spain: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 49. Spain: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 50. Spain: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 51. Asia Pacific Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 52. Asia Pacific: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 53. Asia Pacific: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 54. Asia Pacific: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 55. Asia Pacific: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 56. China Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 57. China: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 58. China: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 59. China: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 60. China: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 61. Japan Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 62. Japan: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 63. Japan: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 64. Japan: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 65. Japan: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 66. India Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 67. India: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 68. India: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 69. India: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 70. India: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 71. Australia Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 72. Australia: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 73. Australia: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 74. Australia: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 75. Australia: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 76. South Korea Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 77. South Korea: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 78. South Korea: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 79. South Korea: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 80. South Korea: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 81. Middle East and Africa Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 82. Middle East and Africa: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 83. Middle East and Africa: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 84. Middle East and Africa: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 85. Middle East and Africa: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 86. UAE Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 87. UAE: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 88. UAE: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 89. UAE: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 90. UAE: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 91. Saudi Arabia Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 92. Saudi Arabia: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 93. Saudi Arabia: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 94. Saudi Arabia: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 95. Saudi Arabia: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 96. South Africa Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 97. South Africa: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 98. South Africa: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 99. South Africa: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 100. South Africa: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 101. South and Central America Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 102. South and Central America: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 103. South and Central America: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 104. South and Central America: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 105. South and Central America: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 106. Brazil Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 107. Brazil: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 108. Brazil: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 109. Brazil: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 110. Brazil: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 111. Argentina Vaccines Market, By Technology – Revenue And Forecast to 2027 (USD Million)
Table 112. Argentina: Vaccines Market, By Disease Indication - Revenue And Forecasts to 2027 (USD Million)
Table 113. Argentina: Vaccines Market, By Hepatitis- Revenue And Forecasts to 2027 (USD Million)
Table 114. Argentina: Vaccines Market, By Route Of Administration - Revenue And Forecasts to 2027 (USD Million)
Table 115. Argentina: Vaccines Market, By Patient Type - Revenue And Forecasts to 2027 (USD Million)
Table 116. Organic Developments Done By Companies
Table 117. Inorganic developments done by Companies
Table 118. Glossary of Terms, vaccines market
LIST OF FIGURES
Figure 1. Vaccines Market Segmentation
Figure 2. Vaccines Segmentation, By Region
Figure 3. Vaccines Market Overview
Figure 4. Conjugate VAccines technology Segment Held Largest Share of vaccines Market
Figure 5. APAC to Show Significant Growth During Forecast Period
Figure 6. Vaccines Market, by Geography (US$ Million)
Figure 7. Global VAccines Market – Leading Country Markets (US$ Million)
Figure 8. Global Vaccines Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia pacific PEST Analysis
Figure 12. Middle East & Africa PEST Analysis
Figure 13. South and central america PEST Analysis
Figure 14. vaccines market impact analysis of driver and restraints
Figure 15. global Vaccines market – Revenue Forecasts and Analysis –2019- 2027
Figure 16. global Vaccines market – by geography Forecasts and Analysis – 2019- 2027
Figure 17. Vaccines Market Share, Technology, 2019 and 2027 (%)
Figure 18. Recombinant Vaccinesinant Vaccines: Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)
Figure 19. Conjugate Vaccines: Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)
Figure 20. Live Attenuated Vaccines Attenuated Vaccines: Vaccines Market - Revenue And Forecasts To 2027 (US$ Million)
Figure 21. Inactivated and Subunit Vaccines Vaccines: Vaccines Market- Revenue And Forecasts to 2027 (US$ Million)
Figure 22. Toxoid Vaccines Vaccines: Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)
Figure 23. Disease Indication MARKET Analysis and Forecasts 2019 and 2027 (%)
Figure 24. DTP (Diphtheria, Tetanus, And Pertussis): Vaccines Market- Revenue And Forecasts To 2027 (US$ Million)
Figure 25. Influenza: Vaccines Market- Revenue And Forecasts to 2027 (US$ Million)
Figure 26. Dengue: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 27. Cytomegalovirus (CMV): Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 28. Hepatitis: Vaccines Market - Revenue And Forecasts To 2027 (US$ Million)
Figure 29. Hepatitis A: Hepatitis Market -Revenue And Forecasts To 2027 (US$ Million)
Figure 30. Hepatitis B: Vaccines Market -Revenue And Forecasts to 2027 (US$ Million)
Figure 31. Respiratory Syncytial Virus (RSV): Vaccines Market - Revenue And Forecasts To 2027 (US$ Million)
Figure 32. Other Diseases: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 33. route of administration MARKET Analysis and Forecasts 2019 and 2027 (%)
Figure 34. Oral: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 35. Injectable: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 36. Other Routes Of Administration: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 37. patient type MARKET Analysis and Forecasts 2019 and 2027 (%)
Figure 38. Pediatric: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 39. Adults: Vaccines Market - Revenue And Forecasts to 2027 (US$ Million)
Figure 40. North America: Vaccines Market, By Country (2019) (usD Million)
Figure 41. North America Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 42. North America: Vaccines Market, By Country, 2019& 2027 (%)
Figure 43. US Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 44. Canada Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 45. Mexico Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 46. Europe Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 47. Europe: Vaccines Market, By Country, 2019 & 2027 (%)
Figure 48. Germany Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 49. UK Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 50. France Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 51. Italy Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 52. Spain Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 53. Asia Pacific Vaccines market revenue Overview, by Country (2019) (us $ mn)
Figure 54. Asia Pacific Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 55. Asia Pacific: Vaccines Market, By Country, 2018 & 2027 (%)
Figure 56. China Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 57. Japan Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 58. India Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 59. Australia Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 60. South Korea Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 61. Middle East & Africa Vaccines market REVENUE, by Country, 2019 (US$ MN)
Figure 62. Middle East and Africa Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 63. Middle East & Africa: Vaccines Market, By Country, 2019 & 2027 (%)
Figure 64. UAE Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 65. Saudi Arabia Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 66. South Africa Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 67. South and Central America Vaccines market REVENUE, by Country, 2019 (US$ MN)
Figure 68. South and Central America Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 69. South and Central America: Vaccines Market, by Country, 2019 and 2027 (%)
Figure 70. Brazil Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 71. Argentina Vaccine Market Revenue And Forecasts to 2027 (US$ Million)
Figure 72. IMPACT OF COVID-19 PANDEMIC IN NORTH AMERICAN COUNTRY MARKETS
Figure 73. IMPACT OF COVID-19 PANDEMIC IN EUROPE COUNTRY MARKETS
Figure 74. IMPACT OF COVID-19 PANDEMIC IN ASIA-PACIFIC COUNTRY MARKETS
Figure 75. IMPACT OF COVID-19 PANDEMIC IN REST OF WORLD COUNTRY MARKETS
Figure 76. Growth Strategies done by the companies in the Market, (%)
The List of Companies - Vaccines Market
- PFIZER INC
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- Sanofi
- Johnson & Johnson Services, Inc
- Panacea Biotec Limited
- AstellasPharma Inc.
- NOVAVAX, INC.
- VBI Vaccines Inc.
- Bavarian Nordic
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the vaccinesmarket.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global vaccinesmarket, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution
Frequently Asked Questions
A vaccine is a biological preparation that provides active acquired immunity against a particular disease. A vaccine consists of an agent that resembles or is a part of the disease-causing microorganism and is often made from weakened or killed forms of the microorganism, its toxins, or one of its surface proteins. The agent triggers the body's immune system to recognize the agent as a threat, destroy it, and to further recognize and destroy any of the microorganisms associated with that agent that it may encounter in the future.
The growth of the market is attributed to the rising prevalence of infectious diseases, growing focus on implementation of immunization programs, and increasing support for vaccine development.
Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, Sanofi, Johnson & Johnson Services, Inc., Panacea Biotec Limited, Astellas Pharma Inc., NOVAVAX, INC., VBI Vaccines Inc., and Bavarian Nordic are some of the major players in the vaccines market.